PhotoHeader_template-products

Products

OncAlert™ Patented Technology:
The Science of Earlier™

The OncAlert™ patented platform is the first and only technologies that measure an unprecedented combination of soluble CD44, a tumor-initiating stem cell biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer.  The foundational science serving as the inspiration behind the OncAlert technology has clinically shown via elevated levels of these markers the possible presence of oral cancer, even prior to observation of visual or physical symptoms.  

To overcome the disparity between the relatively high effective cure rates in early intervention and high mortality rates associated with most diagnosis of oral cancer at a later stage (e.g. Stage III or Stage IV), there exists a need to identify more at-risk patients that are currently going undetected in pre-cancerous stage or in the early stages of cancer progression (e.g. Stage I or Stage II). Addressing this need provides the opportunity to reverse or change adverse lifestyles to lower the risk of potentially developing oral cancer. In situations where cancer has already started, an early screening and intervention could maximize the effectiveness of the treatment while also potentially minimizing the need for aggressive intervention that could significantly impair quality of life post-treatment.

Empowering Healthcare Practitioners with an Accurate, Cost-Effective Solution

Vigilant Biosciences answers this market need through its OncAlert™ Oral Cancer product line’s leveraged and patented technology.  It produces an objective, highly accurate result, empowering healthcare practitioners with an aid in the diagnosis of oral cancer and improving outcomes through earlier intervention.

Through the OncAlert™ Oral Cancer LAB Test or the OncAlert™ Oral Cancer RAPID Test, the OncAlert™ Oral Cancer product line is simple, accurate and cost-effective for the patient.

OncAlert™ Oral Cancer LAB Test

Vigilant Biosciences’ OncAlert™ Oral Cancer LAB Test is a simple, accurate and cost-effective, quantitative aid in diagnosis for clinicians involved in the diagnosis and treatment of oral cancer.

The test is based on patented technology that measure an unprecedented combination of soluble CD44, a tumor-initiating stem cell biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer.  The foundational science behind the OncAlert technology clinically show indications of a possible presence of oral cancer, even prior to observation of visual or physical symptoms.

The test aids the health care professional in making a simple, accurate and cost effective diagnosis.

A Non-Disruptive Test Procedure

OncAlert™ Oral Cancer LAB Test contains an oral rinse which is expelled into a cup and sent to a laboratory for analysis. The painless test takes seconds to administer and is non-disruptive to the exam process.

The OncAlert™ Oral Cancer LAB Test is CE Marked and available for sale in select international markets.  It is not currently available for sale in the United States at this time.

OncAlert™ Oral Cancer RAPID Test

Vigilant Biosciences’ OncAlert™ Oral Cancer RAPID Test is a simple, accurate and cost-effective, qualitative aid in diagnosis for front line healthcare clinicians involved in the screening of oral cancer.

This innovative test is based on patented technology that measure an unprecedented combination of soluble CD44, a tumor-initiating stem cell biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer.  The foundational science behind the OncAlert technology clinically show indications of a possible presence of oral cancer, even prior to observation of visual or physical symptoms. This affordable test is highly accurate, takes seconds to administer, and provides an easy-to-read colorimetric result within minutes indicating presence of CD44 and total protein with respect to pre-determined threshold levels for cutoffs in the specimen.

An Easy, Non-Invasive Test Procedure

OncAlert™ Oral Cancer RAPID Test comprises an oral rinse, which is expelled into a cup, and a test device that is inserted into the sample of the expelled rinse. Within minutes the test device is read by the healthcare professional. The painless test takes seconds to administer and provides clear, objective results within minutes.

The OncAlert™ Oral Cancer RAPID Test is CE Marked and available for sale in select international markets.  It is not currently available for sale in the United States at this time.

QUANTITATIVE

Learn More

QUALITATIVE

Learn More

©2011-2016 Vigilant Biosciences, Inc. All Rights Reserved.

×